Trial · NCT01320982

Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder

NCT01320982, Phase 3, Unknown, Sheba Medical Center

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder. Trials, record NCT01320982. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01320982

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Minocycline, Acetylsalicylic Acid or Pramipexole vs Placebo in Patients With Schizophrenia or Schizoaffective Disorder
NCT number: NCT01320982
Status: Unknown
Phases: Phase 3
Enrollment: 400 participants, estimated
Lead sponsor: Sheba Medical Center
Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: minocycline, pramipexole, acetylsalicylic acid, placebo
First posted: 2011-03-23
Last updated: 2011-03-23

Source ClinicalTrials.gov

Registered outcomes26

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Positive and Negative Syndrome Scale (PANSS)total score	Positive and Negative Syndrome Scale (PANSS) total score at week 8	Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 8 weeks
Primary	Positive and Negative Syndrome Scale (PANSS)total score	Positive and Negative Syndrome Scale (PANSS) total score at week 16	Change from baseline in Positive and Negative Syndrome Scale (PANSS)total score at 16 weeks.
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale (PANSS)positive sub-scale score at week 2	Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale scoreat 2 weeks.
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at week 4 .	Change from baseline in Positive and Negative Syndrome Scale(PANSS) positive sub-scale score at 4 weeks.
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and negative syndrome scale(PANSS) positive sub-scale score at week 8.	Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 8 weeks.
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and negative syndrome scale(PANSS) positive sub-scale score at week 16.	Change from baseline in Positive and negative syndrome scale(PANSS) positive sub-scale score at 16 weeks.
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 2	Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 2 weeks
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 4	Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 4 weeks
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 8	Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 8 weeks
Secondary	Positive and Negative Syndrome Scale (PANSS)	Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at week 16	Change from baseline in Positive and Negative Syndrome Scale (PANSS) negative sub-scale score at 16 weeks

1 to 10 of 26Source ClinicalTrials.gov

See all 26 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
33479775	DERIVED	PubMed
35921506	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01320982

GET https://conductscience.org/api/trials/v1/NCT01320982/registered?page=2

API reference For AI assistants